FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
|Podcasts|January 28, 2022
Vaccine Inequity With Dr. Leonard Friedland
Author(s)Nina Cosdon
In this first episode of Contagion Community, we interview vaccine research scientist Dr. Leonard Friedland about vaccination disparities in the US and around the world.
Advertisement
Welcome to Contagion’s new podcast, Contagion Community, where we delve into some of the social factors that create and widen healthcare disparities.
In surveying our audience, 75% of respondents viewed health equity as a major issue within medicine. Infectious disease often disproportionately occurs along the lines of ethnicity, race, class, gender, education, sexual orientation, geographic location, and more. The entwined nature of healthcare inequity and social factors inhibit us from examining infectious disease objectively, which is why Contagion Community spotlights underserved populations.
Through interviews with experts, we will offer insights into the issues associated with healthcare inequities and examine the strategies being deployed to overcome them.
Contagion Community is a marriage of major conversations occurring in hospitals, labs, academics, and communities.
Vaccines have the power to save lives. However, what happens when they're not distributed equitably?
Today, Associate Editor Nina Cosdon speaks with Leonard Friedland, MD, vice president of Scientific Affairs and Public Health Vaccines at GlaxoSmithKline, about vaccine disparities in the US and around the world.
Enjoy the program and stay tuned for our next episode!
Listen in on the conversation and feel free to offer your feedback on this episode, interest in participating in the podcast, or suggest ideas for future episodes. Please email your correspondence to Nina Cosdon: [email protected].
Advertisement
Related to this article
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
A new study in infants challenges the long-standing belief about the pathogen’s effects in the youngest pediatric population. Senior author Joseph Zackular, PhD, provides insights around his work including how it reshapes gut development and offers potential intervention strategies to shield neonates.
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
The death was reported in Jefferson County where the coroner released a statement announcing it was in an unvaccinated woman.
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
The antiviral did not produce greater symptom improvement than placebo in patients with the condition in the RECOVER-VITAL trial.
GSK will advance its investigational mRNA seasonal flu vaccine candidate, which targets both hemagglutinin and neuraminidase, into a phase 3 trial in September 2026 after the shot outperformed licensed flu vaccines in a phase 2 study.
Advertisement
Advertisement
Trending on Contagion Live
1
US Company Recalls Thousands of Pounds of Uninspected Meat
2
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
3
Measles Update: September 25, 2026
4
How The Food Safety Surveillance Infrastructure Works in the US
5